Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 2 of 7, showing 10 Applications out of 66 total, starting on record 11, ending on 20

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

11.

ECCT/14/09/03   Breast Feeding Study
    An open-label, short-duration, repeat-dose study of breast milk excretion and infant absorption of daily oral Tenofovir Disoproxil Fumarate/Emtricitabine when used by HIV-1 uninfected lactating women    
Principal Investigator(s)
1. Jared Murray Baeten
2. Nelly Rwamba Mugo
Site(s) in Kenya
Partners in Prevention, Thika Site
 
19-08-2015 View

12.

ECCT/14/11/01   ZEBOV Trial
      A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Volunteers in Kilifi, Kenya.                
Principal Investigator(s)
1. Philip Bejon
2. Patricia Njuguna
Site(s) in Kenya
KEMRI Wellcome Trust Research Programme
 
08-12-2014 View

13.

ECCT/14/11/02   A5297
    An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and < 500 cells/mm3   
Principal Investigator(s)
1. VICTOR AKELO
Site(s) in Kenya
KEMRI/CDC CLINICAL RESEARCH CENTRE
 
02-02-2015 View

14.

ECCT/15/04/02  
    Plasma concentration profiles after oral  administration of oleylphosphocholine tablet  formulation: safety, tolerability and pharmacokinetics  of 100 mg single dose in healthy male volunteers.   
Principal Investigator(s)
1. Ravasco Rashid Juma
Site(s) in Kenya
KEMRI
 
15-06-2015 View

15.

ECCT/15/10/01   VRC01 Monoclonal HIV Antibodies Study
    Safety  and  Virologic Effect  Of  A  Human   Monoclonal   Antibody,   VRC-HIVmAb060-00-Ab  (VRCOl),   With Broad  HIV-1  Neutralizing Activity, Administered Intravenously to Adults  During Early Acute HIV Infection.   
Principal Investigator(s)
1. Josphat K Kosgei
Site(s) in Kenya
KEMRI Walter Reed Project Kericho
 
20-03-2016 View

16.

ECCT/15/11/04   VAC040
    A Phase 1/2, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Tolerability, and Immunogenicity of Stretococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide (PATH-wSP) in Healthy Kenya Young Adults (18 - 40years) and Toddlers (12 - 19months)   
Principal Investigator(s)
1. John Anthony Gerard Scott
Site(s) in Kenya
KEMRI-Wellcome Trust Research Program
 
09-02-2016 View

17.

ECCT/16/02/01   ASSESSING THE ACCURACY, USABILITY AND ACCEPTABILITY OF CHILDREN’S AUTOMATED RESPIRATORY MONITOR AT SELECTED CLINICS IN TURKANA COUNTY, KENYA ‘
            ASSESSING THE ACCURACY, USABILITY AND ACCEPTABILITY OF CHILDREN’S AUTOMATED RESPIRATORY MONITOR AT SELECTED CLINICS IN  TURKANA COUNTY, KENYA ‘         
Principal Investigator(s)
1. ISAIAH MWANGI
Site(s) in Kenya
1. lodwar hospital (Turkana county)
 
21-03-2016 View

18.

ECCT/16/06/01   P1115
    Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study   
Principal Investigator(s)
1. Fredrick Sawe
Site(s) in Kenya
KEMRI WALTER REED PROJECT KERICHO
 
25-07-2016 View

19.

ECCT/16/08/03   IMPAACT 2001
    A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection   
Principal Investigator(s)
1. Deborah Chepngeno Langat
Site(s) in Kenya
Kenya Medical Research Institute Walter Reed project
 
27-10-2016 View

20.

ECCT/16/11/02   IMPAACT P1093
    Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and AdolescentsPhase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents   
Principal Investigator(s)
1. Lucy Koech
Site(s) in Kenya
KENYA MEDICAL RESEARCH INSTITUTE/WALTER REED PROJECT HIV PROGRAME
 
28-03-2017 View